Serum Alanine Aminotransferase, Metabolic Syndrome, and Cardiovascular Disease in an Australian Population

American Journal of Gastroenterology

Volumn 104, Issue 7, 2009, Pages 1715-1722

  Olynyk, John K ^a,c,d   Knuiman, Matthew W ^b   Divitini, Mark L ^b   Davis, Timothy M E ^a   Beilby, John ^b,e   Hung, Joseph ^a,f  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c FREMANTLE HOSPITAL   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^e PATHWEST LABORATORY MEDICINE   (Australia)

^f SIR CHARLES GAIRDNER HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; TRIACYLGLYCEROL;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; AUSTRALIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEALTH SURVEY; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MULTIVARIATE ANALYSIS; OBESITY; POPULATION RESEARCH; PRIORITY JOURNAL; RISK ASSESSMENT; SEX DIFFERENCE;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ALANINE TRANSAMINASE; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; COHORT STUDIES; CONFIDENCE INTERVALS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INCIDENCE; LOGISTIC MODELS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; ODDS RATIO; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; WESTERN AUSTRALIA;

EID: 67650417853     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2009.229     Document Type: Article

References (23)

1. World Health Organisation. The World Health Report 2008: Primary Health Care Now More Than Ever 2008.
2. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US Adults: Findings From the third national health and nutrition examination survey. JAMA 2002;287:356-9.
3. Khashab MA, Liangpunsakul S, Chalasani N. Nonalcoholic fatty liver disease as a component of the metabolic syndrome. Curr Gastroenterol Rep 2008;10:73-80.
4. Grundy SM, Cleeman JI, Daniels SR et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement: Executive Summary. Circulation 2005; 112: e285-290.
5. Goessling W, Massaro JM, Vasan RS et al. Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease. Gastroenterology 2008; 135: 1935-44.
6. Ioannou GN, Weiss NS, Boyko EJ et al. Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States. Hepatology 2006; 43: 1145-5.
7. Marchesini G, Bugianesi E, Forlani G et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917-23.
8. Matteoni CA, Younossi ZM, Gramlich T et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-9.
9. Liangpunsakul S, Chalasani N. Unexplained elevations in alanine aminotransferase in individuals with the metabolic syndrome: Results from the Third National Health and Nutrition Survey (NHANES III). Am J Med Sci 2005;329:11-6.
10. Hamaguchi M, Kojima T, Takeda N et al. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 2005;143:722-8.
11. Targher G, Bertolini L, Poli F et al. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 2005; 54: 3541-6.
12. Cull CA, Jensen CC, Retnakaran R et al. Impact of the metabolic syndrome on macrovascular and microvascular outcomes in type 2 diabetes mellitus: United Kingdom prospective diabetes study 78. Circulation 2007; 116: 2119-26.
13. Hung J, Knuiman MW, Divitini ML et al. Prevalence and risk factor correlates of elevated C-reactive protein in an adult Australian population. Am JCardiol 2008;101:193-8.
14. Knuiman MW, Jamrozik K, Welborn TA et al. Age and secular trends in risk factors for cardiovascular disease in Busselton. Aust J Public Health 995;19:375-82.
15. Matthews DR, Hosker JP, Rudenski AS et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9.
16. Olynyk JK, Knuiman MW, Divitini ML et al. Efects of HFE gene mutations and alcohol on iron status, liver biochemistry and morbidity. J Gastroenterol Hepatol 2005; 20: 1435-41.
17. Holman CD, Bass AJ, Rouse IL et al. Population-based linkage of health records in Western Australia: development of a health services research linked database. Aust N Z J Public Health 1999; 23: 453-9.
18. Olynyk JK, Cullen DJ, Aquilia S et al. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med 1999; 341: 718-24.
19. Brea A, Mosquera D, Martin E et al. Nonalcoholic fatty liver disease is associated with carotid atherosclerosis: A case-control study. Arterioscler Thromb Vasc Biol 2005; 25: 1045-50.
20. Parekh S, Anania FA. Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease. Gastroenterology 2007; 132: 2191-207.
21. Kang H, Greenson JK, Omo JT et al. Metabolic syndrome is associated with greater histologic severity, higher carbohydrate, and lower fat diet in patients with NAFLD. Am J Gastroenterol 2006; 101: 2247-53.
22. Adams LA, Lymp JF, St Sauver J et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005;129:13-21.
23. Ekstedt M, Franzen LE, Mathiesen UL et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44: 865 - 73.